Today’s clinical pipelines are at record levels and driven by innovation in approach, including use of AI in discovery and ongoing investment in new and more patient-centric therapies. More and more of these programs follow accelerated development and approval pathways. As a result, target timelines for the start of clinical trials are getting shorter. In this already complex environment, Chemical and Manufacturing Controls should not be the cause for increased risk or delays.  This on-demand presentation covers phase-appropriate development approaches and supply chain solutions for integrated drug substance and drug product projects that can accelerate program timelines and reduce overall complexity and risk.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center